骨改良药治疗骨转移的研究进展

doi:10.3760/cma.j.issn.1673422X.2014.03.021

摘要/Abstract

摘要： 骨改良药是一类缓解因骨转移引起的疼痛、病理性骨折、脊髓压迫、高钙血症等一系列骨相关事件药物的总称。目前主要有双膦酸盐类药物和地诺单抗。骨改良药应用于证实有骨质破坏的骨转移患者，作为化疗、放疗的辅助用药，可以明显提高疗效，延长患者的生存期。此外，中医中药也可以有效缓解骨转移引起的一系列相关症状，改善预后。临床工作中要选择合理的药物，才能最大限度地降低骨转移患者的痛苦，提高生活质量。

关键词: 肿瘤转移, 二膦酸盐类, 地诺单抗

Abstract: Bonemodifying agents (BMA) is a series drugs to alleviate the pain, pathological fractures, spinal cord compression, hypercalcemia, bonerelated events which induced by bone metastases. Bisphosphonate drugs and denosumab are two dominant kinds of BMA at present. It has been proved that BMA is used in bone metastases patients with bone destruction, as adjuvant therapy for chemotherapy and radiotherapy, which can significantly improve the efficacy and prolong the survival of patients. In addition, some traditional Chinese medcine can effectively relieve a series of related symptoms caused by bone metastases and improve prognosis. Choosing right medication in clinical work can maximize the reduction of pain caused by bonerelated events and improve the quality of life of patients.

Key words: Neoplasm metastases, Diphosphonates, Denosumab

孙姗姗, 张月蒙, 高英杰, 高文仓. 骨改良药治疗骨转移的研究进展[J]. 国际肿瘤学杂志, 2014, 41(3): 226-228.

SUN Shan-Shan, ZHANG Yue-Meng, GAO Ying-Jie, GAO Wen-Cang. Research progress of bonemodifying agents in the treatment of bone metastases[J]. Journal of International Oncology, 2014, 41(3): 226-228.

参考文献

［1］ FigueroaMagalhes MC, Miller RS. Bonemodifying agentsas adjuvant therapy for earlystage breast cancer［J］. Oncology (Williston Park), 2012, 26(10):955962. ［2］ Russell RG. Bisphosphonates: the first 40 years［J］. Bone, 2011, 49(1): 219. ［3］ Sallami S, Ben Rhouma S, Cherif K, et al. The role of bisphosphonate in the treatment of bone metastases from prostate cancer［J］. Tunis Med, 2012, 90(7):507511. ［4］ LopezOlivo MA, Shah NA, Pratt G, et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and metaanalysis［J］. Support Care Cancer, 2012, 20(11):29852998. ［5］ Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and MetaAnalysis［J］. Oncologist, 2013, 18(4):353361. ［6］ Murphy L, McCarthy J, McCrate F, et al. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre［J］. Support Care Cancer, 2013, 21(6):15571560. ［7］ Sabry NA, Habib EE. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study［J］. Med Oncol, 2011, 28(2):584590. ［8］ Wang F, Chen W, Chen H, et al. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bonemetastases［J］. Med Oncol, 2013, 30(3): 657657. ［9］ Wang Y, Tao H, Yu X, et al. Clinical significance of zoledronic acid and strontium89 in patients with asymptomatic bone metastases from nonsmallcell lung cancer［J］. Clin Lung Cancer, 2013, 14(3): 254260. ［10］ Drooger JC, van der Padt A, Sleijfer S, et al. Denosumab in breast cancer treatment［J］. Eur J Pharmacol, 2013, 717(13):1219. ［11］ Peters S, Meylan E. Targeting receptor activator of nuclear factorkappa B as a new therapy for bone metastasis in nonsmall cell lung cancer［J］. Curr Opin Oncol, 2013, 25(2):137144. ［12］ Paller CJ, Carducci MA, Philips GK. Management of bone metastases in refractory prostate cancerrole of denosumab［J］. Clin Interv Aging, 2012, 7:363372. ［13］ GomezVeiga F, PonceReixa J, MartinezBreijo S, et al. Advances in Prevention and Treatment of Bone Metastases in Prostate Cancer. Role of RANK/RANKL Inhibition［J］. Actas Urol Esp, 2013, 37(5):292304. ［14］ Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, doubleblind study of denosumab and zoledronic acid［J］. Cancer, 2013, 119(4):832838. ［15］ Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised, phase 3 trials［J］. Eur J Cancer, 2012, 48(16):30823092. ［16］侯恩仁. 补肾填精壮骨方治疗恶性肿瘤骨转移21例［J］. 中国民族民间医药, 2010, 19(3):9191. ［17］蔡亚丽．中西医结合治疗骨转移癌性疼痛80例［J］. 山东中医杂志， 2010， 29(8)：555556. ［18］王向春，裴俊文. 益肾化浊汤治疗骨转移癌痛临床研究［J］. 中医学报, 2012, 27(5):532533. ［19］冯宇, 杨青青, 王海明, 等. 补肾壮骨法治疗乳腺癌骨转移的临床研究［J］. 中华中医药学刊, 2012, 30(6):14121414

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[3]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[4]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[5]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[6]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[7]	马培晗, 张灵敏, 路宁, 张明鑫. 麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.
[8]	吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[9]	赵建昊, 段衍超. 多发性骨髓瘤髓外病变发病机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 55-59.
[10]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[11]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[12]	张绍鹏, 孔远, 潘国强, 朱丽, 王大广. 全身化疗联合腹腔热灌注治疗胃癌1例[J]. 国际肿瘤学杂志, 2022, 49(5): 316-318.
[13]	王斌, 周江云, 刘曦. 不同放疗方案治疗晚期食管鳞状细胞癌的临床价值评析[J]. 国际肿瘤学杂志, 2021, 48(8): 484-488.
[14]	池秀盈, 王鸿彪, 李植锋, 林英城. 复发转移食管鳞状细胞癌治疗进展[J]. 国际肿瘤学杂志, 2021, 48(12): 755-759.
[15]	戴昂, 孙青. CRYAB与肿瘤[J]. 国际肿瘤学杂志, 2020, 47(6): 351-354.